Work

Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

Year: 2020

Type: article

Source: Leukemia

DOI: 10.1038/s41375-020-0834-9

Authors: Hans C. Lee, Noopur S. Raje, Ola Landgren, Vijay V. Upreti, Jin Wang, Ariel A. Avilion, Xuguang Hu, Erik Rasmussen, Gataree Ngarmchamnanrith, Hisaki Fujii, Andrew Spencer

Institutions: The University of Texas MD Anderson Cancer Center, Harvard University, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Amgen (United States), The Alfred Hospital, Monash University

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Amgen

OpenAlex ID: W3016933523

FWCI: 6.748

Cites: 11

Cited by: 66

Related to: 10